In BRAF-mutant melanoma sustained mTORC1 signaling could be driven by alternative mechanisms of ERK activation or concomitant activation of the PI3K-Akt pathway, thus promoting resistance to RAF and MEK inhibitors. Here, AKT1 is linked to melanoma.